Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Regulatory Science Infrastructure Gets $25 Million Push In Budget

This article was originally published in The Tan Sheet

Executive Summary

A $25 million, cross-center scientific modernization effort proposed in FDA's fiscal 2011 budget targets gaining the expertise and infrastructure needed to assess products of the future - such as biosimilars and those based on stem cells and nanotechnology

You may also be interested in...



FDA Proposes Expanding User Fees To Cosmetics Among New Areas

The White House requests a 17% increase in FDA’s overall budget to $4.5 billion, including $855 million in direct appropriations for CFSAN, about $10 million less than its fiscal 2012 appropriation, and $473 million for CDER, about $5 million less than its current appropriation.

FDA Proposes Expanding User Fees To Cosmetics Among New Areas

The White House requests a 17% increase in FDA’s overall budget to $4.5 billion, including $855 million in direct appropriations for CFSAN, about $10 million less than its fiscal 2012 appropriation, and $473 million for CDER, about $5 million less than its current appropriation.

President's Budget Proposal Points To Expanding FDA User Fees

President Obama's fiscal 2012 budget request concurs with FDA in recommending that Congress expand the type of user fees that industry pays for food safety enforcement reform.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS103816

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel